There may be no drug-pricing myth more pernicious than the idea that the NIH does all the drug research, and companies just sweep in at the eleventh hour, ram medicines

It’s World AIDS Day today. This used to be a much high-profile event, with consistent media coverage. That’s changed, slowly, over the two decades or so, which -- I fear

I’m finally through uploading the transcripts from almost all** of the CMS patient-focused listening sessions around the 10 drugs slated for price controls under the Inflation Reduction Act. You can

There’s a lot to go through this morning. Let’s get at it. I’m thinking about rare diseases this morning for a couple of reasons.  First, there is this JAMA Internal

I’ve been on the record for a while now arguing that the conversation around obesity medicines ought not be a debate about whether the medicines are “worth it” -- it

I love Thanksgiving for a number of reasons, the two biggest of which are 1) pie and 2) the explicit focus on gratitude. This year, I’ve been especially fortunate. As

So I wasn’t gone that long, but I feel like I missed a ton. Eschewing the usual format in favor of some quick hits, grouped by importance. BIG DEALS The

My goal for The Arc is to have some sort of a spin on some element of the news, rather than just a Chat-GPT-sounding summary of whatever tabs I have

Generally, I try to reserve Inflection Point for breaking news, and it’s tough to justify highlighting a Wall Street Journal editorial in this slot. Bear with me.  The WSJ editorial

Programming Note: Cost Curve will be off Thursday, Friday, and next Monday so that I can watch my social media manager/future Terrier do her thing against some of Canada’s best